Pushing the boundaries of siRNA targeting and delivery

Although siRNA therapeutics have made significant progress in terms of their stability and safety, key challenges relating to the specificity and efficiency of delivery remain. David McCall, Senior Editor, BioInsights, talks to Merle Fuchs, Co-Founder and CEO of PRAMOMOLECULAR GmbH, about promising approaches to address this issue and continue expanding the range of applications available to oligonucleotide therapeutics.

Please enter your email to access content Read now